ConductScience.org, home

Comparison · NCT00167180-c8d4704e

DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg vs DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg: Number of Patients Alive

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg vs DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg: Number of Patients Alive. Trial comparisons, record NCT00167180-c8d4704e. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00167180-c8d4704e

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.20.07050.452wilson
Risk in group 20.4760.3340.623wilson
Risk difference, group 1 minus group 2-0.276-0.4720.0132newcombe hybrid score
Risk ratio, group 1 over group 20.420.1451.21log
Odds ratio, group 1 over group 20.2750.06761.12log
Number needed to treat, for one fewer participant with the outcome on DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg than on DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg3.62from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kgCyclophosphamide 60mg/kg IV over 2 hours Fludarabine 25 mg/m2 IV over 30 minutes DLI Cell Dose 1.0 x 10\^8 CD3+ T-cells/kg315OG000
Group 2DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kgCyclophosphamide 60mg/kg IV over 2 hours Fludarabine 25 mg/m2 DLI Cell Dose 0.5 x 10\^8 CD3+ T-cells/kg2042OG001

Outcome

Type
PRIMARY
Title
Number of Patients Alive
Description
The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer. Also called survival rate.~Overall survival will be defined as time from date of enrollment to date of death or censored at the date of last documented contact for patients still alive.
Time frame
1 Year
Population

Source ClinicalTrials.gov

Trial

Title
Post Transplant Donor Lymphocyte Infusion
NCT number
NCT00167180
Phases
PHASE2
Conditions
Leukemia, Myeloid, Chronic, Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome, Leukemia, Lymphocytic, Acute, Leukemia, Lymphocytic, Chronic, AML
Interventions
Donor Lymphocyte Infusion, Induction Chemotherapy
Lead sponsor
Masonic Cancer Center, University of Minnesota
Results first posted
2017-07-11

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00167180-c8d4704e